Amanda J. Novak
Research Subjects
Amanda J. Novak has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Mark Eric Kohler
Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, USA
12 shared publications - Alana L. Keller
University of Colorado Anschutz Medical Campus 1 Aurora, CO
9 shared publications - Catherine Pham-Danis
University of Colorado Anschutz Medical Campus 4
9 shared publications - Daniel W. Sherbenou
Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
9 shared publications - Denis Ohlstrom
Georgia Institute of Technology 2 Atlanta, GA
9 shared publications - Jeremy T. Rahkola
Rocky Mountain Regional Veteran Affairs Medical Center 5 Aurora, Colorado
9 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
Multiple myeloma is a plasma cell malignancy that is mostly incurable, even with recent advances in treatment such as B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T cells and bispecific T cell–engaging (TCE) antibodies. To better understand this treatment resistance, we examined multiple myeloma cells that persisted after these treatments and consistently observed CD45 upregulation as part of a resistance program. Bone marrow samples were treated ex vivo with BCMA CAR T cells, TCE antibodies (elranatamab, SAR442257), or activated T cells and analyzed via flow cytometry. CD45 upregulation was validated in patient samples before and after idecabtagene vicleucel therapy (anti–BCMA CAR T-cell therapy) and using an in vivo mouse model of disseminated multiple myeloma. Persisting multiple myeloma cells exhibited focal CD45 surface patches. Mechanistic studies implicated secreted HSP70, whereas bulk RNA sequencing revealed increased LAG-3, IFNγ signaling, and PD-L1 expression. These findings suggest that T cell–redirecting therapy (TCRT) drives an immunoevasive phenotype defined by CD45 upregulation and immune checkpoint activation, supporting combination strategies of TCRT with checkpoint inhibitors to overcome resistance in relapsed/refractory multiple myeloma.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
Multiple myeloma is a plasma cell malignancy that is mostly incurable, even with recent advances in treatment such as B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T cells and bispecific T cell–engaging (TCE) antibodies. To better understand this treatment resistance, we examined multiple myeloma cells that persisted after these treatments and consistently observed CD45 upregulation as part of a resistance program. Bone marrow samples were treated ex vivo with BCMA CAR T cells, TCE antibodies (elranatamab, SAR442257), or activated T cells and analyzed via flow cytometry. CD45 upregulation was validated in patient samples before and after idecabtagene vicleucel therapy (anti–BCMA CAR T-cell therapy) and using an in vivo mouse model of disseminated multiple myeloma. Persisting multiple myeloma cells exhibited focal CD45 surface patches. Mechanistic studies implicated secreted HSP70, whereas bulk RNA sequencing revealed increased LAG-3, IFNγ signaling, and PD-L1 expression. These findings suggest that T cell–redirecting therapy (TCRT) drives an immunoevasive phenotype defined by CD45 upregulation and immune checkpoint activation, supporting combination strategies of TCRT with checkpoint inhibitors to overcome resistance in relapsed/refractory multiple myeloma.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
Combination Treatment of Ruxolitinib and Elranatamab was not Synergistically Cytotoxic to MM Cells
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
Combination Treatment of Ruxolitinib and Elranatamab was not Synergistically Cytotoxic to MM Cells
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
CD45 and IFN genes are upregulated at the RNA level in CD45-positive MM.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
CD45 and IFN genes are upregulated at the RNA level in CD45-positive MM.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
HSP70-mediated protein upregulation in CD45+ MM.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
HSP70-mediated protein upregulation in CD45+ MM.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
Clinical characteristics of patients studied for CD45 changes in response to T cell–redirecting therapies
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
Clinical characteristics of patients studied for CD45 changes in response to T cell–redirecting therapies
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
Profiling MM drug sensitivity and CD45 upregulation with CAR-T cell therapy My-DST.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
Profiling MM drug sensitivity and CD45 upregulation with CAR-T cell therapy My-DST.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
Profiling MM drug sensitivity and CD45 upregulation with T cell engager My-DST.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
Profiling MM drug sensitivity and CD45 upregulation with T cell engager My-DST.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
A soluble factor induces a sustained upregulation of CD45 on H929 cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype
A soluble factor induces a sustained upregulation of CD45 on H929 cells.
- 10 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (8) , 1307-1321
Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype
Multiple myeloma (MM) is plasma cell malignancy that is mostly incurable, even with recent advances in treatment such as BCMA-targeted chimeric antigen receptor (CAR) T cells and bispecific T cell–engaging antibodies (TCEs). To better understand this treatment resistance, we examined MM cells that persisted after these treatments and consistently observed CD45 upregulation as part of a resistance program. Bone marrow samples were treated ex vivo with BCMA CAR T cells, TCEs (elranatamab, SAR442257), or activated T cells, and analyzed by flow cytometry. CD45 upregulation was validated in patient samples before and after idecabtagene vicleucel therapy (anti-BCMA CAR T-cell therapy), and by using in an in vivo mouse model of disseminated MM. Persisting MM cells exhibited focal CD45 surface patches. Mechanistic studies implicated secreted HSP70, while bulk RNA-sequencing revealed increased LAG-3, IFN-γ signaling, and PD-L1 expression. These findings suggest T cell–redirecting therapy (TCRT) drives an immuno-evasive phenotype defined by CD45 upregulation and immune checkpoint activation, supporting combination strategies of TCRT with checkpoint inhibitors to overcome resistance in relapsed/refractory MM.
- 10 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (8) , 1307-1321
Multiple Myeloma Cells Resistant to T-cell Therapies Exhibits a CD45+ Immune Evasive Phenotype
Multiple myeloma (MM) is plasma cell malignancy that is mostly incurable, even with recent advances in treatment such as BCMA-targeted chimeric antigen receptor (CAR) T cells and bispecific T cell–engaging antibodies (TCEs). To better understand this treatment resistance, we examined MM cells that persisted after these treatments and consistently observed CD45 upregulation as part of a resistance program. Bone marrow samples were treated ex vivo with BCMA CAR T cells, TCEs (elranatamab, SAR442257), or activated T cells, and analyzed by flow cytometry. CD45 upregulation was validated in patient samples before and after idecabtagene vicleucel therapy (anti-BCMA CAR T-cell therapy), and by using in an in vivo mouse model of disseminated MM. Persisting MM cells exhibited focal CD45 surface patches. Mechanistic studies implicated secreted HSP70, while bulk RNA-sequencing revealed increased LAG-3, IFN-γ signaling, and PD-L1 expression. These findings suggest T cell–redirecting therapy (TCRT) drives an immuno-evasive phenotype defined by CD45 upregulation and immune checkpoint activation, supporting combination strategies of TCRT with checkpoint inhibitors to overcome resistance in relapsed/refractory MM.
- Open Access
- 13 November 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (11) , e011971
Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival
Background: Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-modulated escape remains common. Multiple strategies to simultaneously target CD19 and CD22 have been able to reduce antigen-modulated escape but not completely eliminate relapse. A bicistronic CAR construct consisting of a CD19 CAR incorporating the CD28 costimulatory domain paired with a CD22 CAR incorporating a 4-1BB costimulatory domain (CD19xCD22) demonstrated superior preclinical activity compared with other configurations and is currently under clinical investigation ( NCT05098613 , NCT05442515 , NCT06559189 ). We hypothesized that simultaneous activation of CD28-containing and 4-1BB-containing CAR molecules not only allows for targeting of both antigens but creates a unique signal which enhances CAR T-cell function and efficacy. Methods: We tested CD19xCD22 CAR T-cells generated from primary human T-cells against NALM6 with wild-type expression of CD19 and CD22 (CD19+/CD22+) or CRISPR/Cas9 knockout of one or both antigens (CD19+/CD22−, CD19−/CD22+, CD19−/CD22−) to interrogate the effect of dual-CAR stimulation on T-cell function, signaling, and in vivo efficacy in xenograft models. Results: In vitro proliferation and cytokine production of CD19xCD22 CAR T-cells were primarily driven by activation of the CD19-28z CAR, however the CD22-BBz CAR drove equivalent cytotoxicity. Dual-CAR stimulation of CD19xCD22 CAR T-cells decreased leukemia relapse and improved survival in xenograft models. This increase in efficacy was associated with increased signaling through the phospholipase C-gamma 1 and nuclear factor of activated T-cells pathway after dual-CAR stimulation. Dual-CAR stimulation also led to decreased expression of markers associated with T-cell exhaustion in persistent CD19xCD22 CAR T-cells. Conclusions: Stimulation of both CAR molecules in a CD19xCD22 bicistronic CAR construct impacts downstream signaling events within the CAR T-cell and subsequently drives a more efficacious in vivo response with evidence of decreased exhaustion in persisting cells. These data suggest that bicistronic CAR platforms have the potential to not only target two antigens to prevent antigen-modulated escape but can be engineered to improve multiple facets of CAR T-cell biology, such as mitigating exhaustion, thereby overcoming multiple mechanisms known to drive relapse in current CAR T-cell therapies.
- 13 November 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (11) , e011971
Open AccessIncreased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival
Background: Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-modulated escape remains common. Multiple strategies to simultaneously target CD19 and CD22 have been able to reduce antigen-modulated escape but not completely eliminate relapse. A bicistronic CAR construct consisting of a CD19 CAR incorporating the CD28 costimulatory domain paired with a CD22 CAR incorporating a 4-1BB costimulatory domain (CD19xCD22) demonstrated superior preclinical activity compared with other configurations and is currently under clinical investigation ( NCT05098613 , NCT05442515 , NCT06559189 ). We hypothesized that simultaneous activation of CD28-containing and 4-1BB-containing CAR molecules not only allows for targeting of both antigens but creates a unique signal which enhances CAR T-cell function and efficacy. Methods: We tested CD19xCD22 CAR T-cells generated from primary human T-cells against NALM6 with wild-type expression of CD19 and CD22 (CD19+/CD22+) or CRISPR/Cas9 knockout of one or both antigens (CD19+/CD22−, CD19−/CD22+, CD19−/CD22−) to interrogate the effect of dual-CAR stimulation on T-cell function, signaling, and in vivo efficacy in xenograft models. Results: In vitro proliferation and cytokine production of CD19xCD22 CAR T-cells were primarily driven by activation of the CD19-28z CAR, however the CD22-BBz CAR drove equivalent cytotoxicity. Dual-CAR stimulation of CD19xCD22 CAR T-cells decreased leukemia relapse and improved survival in xenograft models. This increase in efficacy was associated with increased signaling through the phospholipase C-gamma 1 and nuclear factor of activated T-cells pathway after dual-CAR stimulation. Dual-CAR stimulation also led to decreased expression of markers associated with T-cell exhaustion in persistent CD19xCD22 CAR T-cells. Conclusions: Stimulation of both CAR molecules in a CD19xCD22 bicistronic CAR construct impacts downstream signaling events within the CAR T-cell and subsequently drives a more efficacious in vivo response with evidence of decreased exhaustion in persisting cells. These data suggest that bicistronic CAR platforms have the potential to not only target two antigens to prevent antigen-modulated escape but can be engineered to improve multiple facets of CAR T-cell biology, such as mitigating exhaustion, thereby overcoming multiple mechanisms known to drive relapse in current CAR T-cell therapies.